Amorepacific and Johns Hopkins School of Medicine's Joint Research Program 'NBRI' Participants Present Latest Findings
Skin anti-aging and immunity effects of Amorepacific's two proprietary ingredients,
'RE.D Flavonoid' and 'Senomune' revealed at the 2025 SID Annual Meeting
SEOUL, South Korea, May 16, 2025 /CNW/ -- Amorepacific has demonstrated the efficacy of its two proprietary ingredients in improving skin aging and immune response through the NBRI program, jointly operated with Johns Hopkins School of Medicine. The findings were presented at the 2025 SID (Society for Investigative Dermatology) Annual Meeting in San Diego, California, last week.
NBRI (New Beauty Research Initiative) is a collaborative research program that Amorepacific has maintained with the Department of Dermatology at Johns Hopkins School of Medicine since 2022. The two organizations conduct multifaceted research cooperation on skin aging. At this year's SID meeting, NBRI program participants Professor Anna Chien's research team presented the efficacy of Amorepacific's bio-flavonoid ingredient, RE.D Flavonoid, and Professor Martin Alphonse's research team presented the benefits of the green tea-derived ingredient, Senomune.
Professor Anna Chien's team confirmed that RE.D Flavonoid, derived from the camellia plant, effectively improves photo-aging symptoms on the face and neck area without irritation. Notable improvements were observed across significant signs of skin aging, including fine lines, skin texture, pores, radiance, and pigmentation, with substantial changes in skin texture and radiance appearing from the eighth week of use. This research was based on long-term results from North American consumers of diverse ethnicities who used RE.D Flavonoid for six months. The study indicates that RE.D Flavonoid works by blocking signal transmission in skin aging and inhibiting collagen damage, which is crucial for skin elasticity.
Professor Martin Alphonse's team revealed that Senomune, a saponin component from green tea extract, mitigates immune cell damage and inflammatory responses caused by particulate matter (PM). The team also confirmed the potential for Senomune to reduce immune aging and chronic inflammatory reactions due to external environmental factors by balancing the metabolic functions of immune cells. This research was conducted using peripheral blood mononuclear cells (PBMC) from humans, and researchers observed reduced stress responses in immune cells to environmental harmful elements in groups pre-treated with the ingredient.
Dr. Suh Byung-fhy, CTO and Head of Amorepacific's R&I Center, stated, "The ongoing NBRI collaborative research program for Skin Longevity of our global customers provides a valuable opportunity to demonstrate the scientific excellence of Amorepacific's slow-aging skincare technology," adding, "Amorepacific will continue to focus on beauty solution research aimed at activating the skin's fundamental recovery capabilities beyond mere symptom improvement."
The Society for Investigative Dermatology (SID) is an organization dedicated to advancing the sciences relevant to skin disease and has held annual meetings since its establishment in 1937. At this year's 82nd conference, more than 1,600 researchers, clinicians, and dermatology residents from around the world gathered to present over 1,200 of the latest skin research findings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 days ago
- Cision Canada
ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, May 30, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a Trial in Progress poster for its first-in-human, Phase 1a/1b clinical trial of IMGS-001 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 30 to June 3, 2025. This Phase 1a/1b first-in-human, open-label, multicenter study (NCT06014502) includes a dose escalation and an expansion portion to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. The study will enroll approximately 25 patients in Phase 1a and up to 250 in Phase 1b. The first three of five planned dose cohorts have completed without any dose limiting toxicities (DLTs), with cohort 4 (10 mg/kg) now enrolling. "This clinical trial is an important first step to understand how IMGS-001 may potentially remove immunosuppressive cells while improving PD-1 pathway blockade to treat otherwise immunoresistant tumors that represent a significant unmet medical need," stated Charles Schweizer, PhD, Senior Vice President of Clinical Development at ImmunoGenesis. "We are pleased to discuss the study plan and progress at this important conference as we look ahead to sharing results." "We are encouraged by the early performance of IMGS-001 as we proceed with Phase 1 dose escalation in patients with a variety of advanced solid tumors," said James Barlow, President and CEO of ImmunoGenesis. "Initial low doses administered to date have been well-tolerated with no dose-limiting toxicities, and we are seeing promising early signs of anti-tumor activity in patients who have failed prior treatments. IMGS-001 has the potential to be a foundational therapy for immune-excluded tumors, addressing a major unmet need." ASCO Poster Presentation Title: A Phase 1a/1b study to evaluate the safety, tolerability, Pharmakokinetics, and anti-tumor activity of IMGS-001 in Patients with relapsed or refractory advanced solid tumors. Abstract: TS2686 | Poster Bd #: 324a Track: Developmental Therapeutics—Immunotherapy Location: Hall A -Posters and Exhibits | On Demand Time: June 2, 2025, 1:30 PM – 4:30 PM CDT About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001, the lead program at ImmunoGenesis, is a PD-L1/PD-L2 dual-specific monoclonal antibody with engineered cytotoxic effector function. IMGS-001 is the first molecule in clinical testing to target PD-L2 in addition to PD-L1, potentially improving blockade of the PD-1 pathway. The engineered effector function may enable IMGS-001 to eliminate immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove higher response rates in head-to-head studies compared to currently available immunotherapies. IMGS-001 may provide a new foundational therapy with its innovative multitasking mechanism of superior blockade and cytotoxic effector function. IMGS-001 is being developed with support from the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094 as well as an investment from the Cancer Focus Fund, LP. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc.
Globe and Mail
27-05-2025
- Globe and Mail
Extendicare Announces Voting Results for its 2025 Annual and Special Meeting of Shareholders
MARKHAM, Ontario, May 27, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. ('Extendicare' or the 'Company') (TSX: EXE) today announced the results of matters voted on at its annual and special meeting of shareholders held on May 27, 2025 (the 'Meeting'). The voting results for each of the matters considered at the Meeting are presented below. The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 47,282,730, representing 56.41% of the Company's outstanding common shares. 1. Election of Directors On a vote by ballot, the election of the following nine nominees as directors of the Company to hold office until the next annual meeting of the Company, or until their respective successors are elected or appointed, was approved. The results of the vote on this matter are set out below. Nominee Votes For % Votes Against % Norma Beauchamp 46,177,249 98.73 592,188 1.27 Donald E. Clow 46,603,908 99.65 165,530 0.35 Dr. Michael Guerriere 46,645,613 99.74 123,825 0.26 Sandra L. Hanington 43,999,570 94.08 2,769,867 5.92 Brent Houlden 46,587,443 99.61 181,995 0.39 Heather-Anne Irwin 46,609,774 99.66 159,664 0.34 Donna E. Kingelin 46,644,110 99.73 125,328 0.27 Samir Manji 46,093,412 98.55 676,026 1.45 Alan D. Torrie 46,576,008 99.59 193,430 0.41 2. Appointment of Auditors On a vote by show of hands, the appointment of KPMG LLP as the auditors of the Company to hold office until the close of the next annual meeting of the Company at such remuneration as shall be fixed by the board of directors of the Company was approved. The results of the vote on this matter are set out below. Votes For % Votes Withheld % 41,212,290 87.18 6,059,857 12.82 3. Approval of Unallocated Entitlements Under and Amendment to Extendicare's Long Term Incentive Plan On a vote by show of hands, the ordinary resolution to approve all unallocated securities, rights or other entitlements under Extendicare's Long Term Incentive Plan and an amendment to the amendment provisions thereof, all as more particularly described in the Company's management information and proxy circular dated April 17, 2025 (the 'Information Circular'), was approved. The results of the vote on this matter are set out below. Votes For % Votes Against % 45,373,757 97.04 1,385,498 2.96 4. Approach to Executive Compensation On a vote by ballot, a non-binding advisory resolution to accept the Company's approach to executive compensation disclosed in the Company's Information Circular was approved. The results of the vote on this matter are set out below. Votes For % Votes Against % 44,185,736 94.48 2,583,675 5.52 About Extendicare Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of a growing seniors' population, inspired by our mission to provide people with the care they need, wherever they call home. As at March 31, 2025, we operated a network of 122 long-term care homes (50 owned, 72 under management contracts), delivered approximately 11.2 million hours of home health care services annually, and provided group purchasing services to third parties representing approximately 148,200 beds across Canada. Extendicare proudly employs approximately 24,000 qualified, highly trained and dedicated team members who are passionate about providing high-quality care and services to help people live better. Forward-looking Statements Information provided by Extendicare from time to time, including this release, contains or may contain forward-looking statements concerning anticipated future events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation: statements regarding its dividend levels, business operations, business strategy, growth strategy, results of operations and financial condition. Forward-looking statements can often be identified by the expressions 'anticipate', 'believe', 'estimate', 'expect', 'intend', 'objective', 'plan', 'project', 'will', 'may', 'should' or other similar expressions or the negative thereof. These forward-looking statements reflect the Company's current expectations regarding future results, performance or achievements and are based upon information currently available to the Company and on assumptions that the Company believes are reasonable. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare's forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at and on Extendicare's website at Except as required by applicable securities laws, the Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Extendicare contact:
Cision Canada
23-05-2025
- Cision Canada
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer SAN DIEGO and CALGARY, AB, May 23, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment. "For the first time, we're able to map the cascade of immune responses stimulated by pelareorep," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. "It starts with the expansion of anti-reovirus T cells, followed by the upregulation of chemokines that mediate the expansion of pre-existing TIL clones in the blood. These T cells can now return to the tumor and attack it, resulting in a reduction in tumor size. Pelareorep-mediated upregulation of chemokines also makes the tumor microenvironment immunologically active and able to actively recruit cancer-specific T cells to the tumor. These findings deepen our understanding of pelareorep's ability to convert immunologically cold tumors into immunologically active ones that may benefit from pelareorep-based combination therapy." Abstract Number: 2562 Title: Role of pelareorep in activating anti-tumor immunity in PDAC. Presentation Type: Poster Session Title: Developmental Therapeutics – Immunotherapy Session Date and Time: June 2, 2025, 1:30 - 4:30 p.m. CT A copy of the ASCO presentation will be available on the Media page of Oncolytics' website (LINK) following the conclusion of the meeting. Highlights from the poster and abstract include: Pelareorep initiates the expansion of reovirus-specific T cells that are associated with favorable clinical responses at week 24 Pelareorep increases cytokines and chemokines associated with altering the TME to allow anti-viral and anti-tumor T cells to attack the tumor The presence of TIL clones in the blood before treatment and the expansion of these clones in the blood post-treatment are associated with favorable clinical responses Previously reported efficacy results from GOBLET Cohort 1, which is evaluating the therapeutic regimen of pelareorep, nab-paclitaxel, gemcitabine, and atezolizumab (Tecentriq ®) in first-line metastatic PDAC patients, showed a 62% overall response rate, an 85% disease control rate, and a 45% 12-month survival rate About GOBLET The GOBLET (G astrointestinal tum O rs exploring the treatment com B inations with the oncolytic reovirus pe L ar E orep and an T i-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany and is being managed by AIO-Studien-gGmbH. The primary endpoints of the study are objective response rate (ORR) and/or disease control rate assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study comprises five treatment groups: Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1 st line advanced/metastatic pancreatic cancer patients; Pelareorep in combination with atezolizumab in 1 st line MSI (microsatellite instability)-high metastatic colorectal cancer patients; Pelareorep in combination with atezolizumab and TAS-102 in 3 rd line metastatic colorectal cancer patients Pelareorep in combination with atezolizumab in 2 nd line advanced and unresectable anal cancer patients; and Pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients. Any cohort meeting pre-specified efficacy criteria in Stage 1 may be advanced to Stage 2 and enroll additional patients. About AIO AIO-Studien-gGmbH (AIO) emerged from the study center of the medical oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. Tecentriq ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] SOURCE Oncolytics Biotech® Inc.
